SCHEMBL5457591

SCHEMBL5457591

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4cc(F)ccc4F)cc3)cc2CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.36
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR2A P28223 7/20 0.34
HTR2C P28335 7/20 0.34
KCNH2 Q12809 3/20 0.34
DRD2 P14416 3/20 0.34
HTR6 P50406 7/20 0.34
DRD3 P35462 2/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
MOGAT2 Q3SYC2 1/20 0.33
NTRK1 P04629 1/20 0.33
CA2 P00918 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455409 0.92 HTR2A (0.41) USP2SMN1; SMN2HTR2AHTR2CKCNH2
SCHEMBL5452671 0.91 USP2 (0.34) USP2SMN1; SMN2HTR2AHTR2CKCNH2
SCHEMBL5445721 0.90 USP2 (0.41) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5444653 0.89 HTR2A (0.34) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5453940 0.89 HTR6 (0.37) RORCUSP2SMN1; SMN2HTR2AHTR2C
SCHEMBL5467092 0.89 HTR2A (0.37) HTR2AHTR2CKCNH2DRD2HTR6
SCHEMBL5462505 0.88 P2RX7 (0.38) USP2SMN1; SMN2HTR2AHTR2CKCNH2
SCHEMBL5448741 0.87 USP2 (0.39) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5450607 0.87 HTR2A (0.37) RORCUSP2SMN1; SMN2HTR2AHTR2C
SCHEMBL5448944 0.87 HTR2A (0.36) RORCUSP2SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 RORC 1630/4885USP2 4595/4885SMN1; SMN2 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.